Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox vs Mirabegron + Solifenacin in Detrusor Overactivity
NCT05968885Phase 4Recruiting
- Sponsor
- Mackay Memorial Hospital
- Start
- Oct 2021
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mirabegron and solifenacin in detrusor overactivity, sponsored by Mackay Memorial Hospital. Primary endpoints: Urinary Distress Inventory at 1 year and Incontinence Impact Questionnaire at 1 year. Started Oct 2021; status: recruiting.
02
Drugs
mirabegronsolifenacin
03
Conditions
detrusor overactivity
Beyond the preview
Go deeper on NCT05968885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968885.